Aisling Capital Management LP
CIK
1766721
Location
NEW YORK, NY
Portfolio Value
Small
$476,288,949
Diversification
Highly concentrated
Filing Date
Global Rank
#2,689
/ 8,586
▲ 37
Top Industry
Biotechnology
98.3%
3Y Alpha vs SPY
+19.1%
Period ended 3 months ago
Filed May 5, 2026 · 42d
25 quarters · since Mar 2020
Clone Performance
Jun 2023–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+176.3%
SPY
+78.1%
Annualised alpha
+19.1%
Max drawdown
−42.7%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
13 positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
79.4%
−1.9 pts
Top 5
95.5%
−0.1 pts
Top 10
99.5%
−0.1 pts
HHI
6,381
Highly concentrated−294
Portfolio Trend
25 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $476,288,949 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
3 positions
Trimmed
Positions the filer reducedNo qualifying positions this quarter.
New Positions
Positions the filer opened this quarter
1 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| EPRX | Eupraxia Pharmaceuticals Inc. | 325,000 | $2,353,000 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
1 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| CALC | CalciMedica, Inc. | 521,114 | $3,434,141 | |
| No positions match the current search. | ||||
13 positions ·
$476,288,949 total
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| BBIO |
BridgeBio Pharma, Inc.
Healthcare
|
Held | 5,089,611 | $377,954,512 | 79.35% | |
| SNDX |
Syndax Pharmaceuticals Inc
Healthcare
|
Held | 1,316,806 | $30,760,588 | 6.46% | |
| GLUE |
Monte Rosa Therapeutics, Inc.
Healthcare
|
Added | 1,555,664 | $25,590,672 | 5.37% | |
| BCAX |
Bicara Therapeutics Inc.
Healthcare
|
Held | 568,919 | $11,315,798 | 2.38% | |
| BBOT |
BridgeBio Oncology Therapeutics, Inc.
Healthcare
|
Added | 1,018,018 | $9,111,261 | 1.91% | |
| CMPS |
COMPASS Pathways plc
Healthcare
|
Added | 1,432,336 | $7,920,818 | 1.66% | |
| SRRK |
Scholar Rock Holding Corp
Healthcare
|
Held | 77,031 | $3,786,843 | 0.80% | |
| BMEA |
Biomea Fusion, Inc.
Healthcare
|
Held | 2,048,757 | $3,134,598 | 0.66% | |
| EPRX |
Eupraxia Pharmaceuticals Inc.
Healthcare
|
NEW | 325,000 | $2,353,000 | 0.49% | |
| URGN |
UroGen Pharma Ltd.
Healthcare
|
Held | 108,000 | $1,941,840 | 0.41% | |
| ACRS |
Aclaris Therapeutics, Inc.
Healthcare
|
Held | 434,455 | $1,629,206 | 0.34% | |
| MRKR |
Marker Therapeutics, Inc.
Healthcare
|
Held | 325,370 | $422,981 | 0.09% | |
| OKUR |
OnKure Therapeutics, Inc.
Healthcare
|
Held | 88,607 | $366,832 | 0.08% |